ReviewRecent patents on biotechnology2026
Cognition, Diagnosis, and Treatment of Alzheimer's Disease: A Review.
Review in Recent patents on biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As the global population ages, the health of older adults has become a growing concern. Alzheimer's disease (AD) is a common ailment affecting older adults, but the diagnosis and treatment of AD are difficult given our insufficient understanding of the disease. This review article and patents aim to provide reliable information for patients and their families by presenting a detailed overview of the pathogenic factors, diagnostic methods, and clinical manifestation of AD, as well as advances in drug and physical therapies. The information presented here should help provide a more comprehensive understanding of AD for patients and their families and encourage family- or self-screening based on clinical manifestations, thus improving early AD detection. In addition, the current treatment methods for AD are summarized. Although a goldstandard treatment for AD is yet to be developed, controlled-release therapies and medications that slow disease progression or improve cognitive function are available. The appropriate treatment method depends on the patient's diagnosis and the local medical level, and the effectiveness of the treatments may vary. Therefore, improving our understanding of AD and cognition-related symptoms in the public is necessary to improve early AD diagnoses. This review provides information that will facilitate self-screening for AD based on clinical manifestations, which can improve the early clinical diagnosis rate.
Indexed as
Identifiers
40539354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.